Phase 3 Alzheimer's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 50 and 80 years old (male or female)
- You have signed and dated a consent form, or a legal representative has done so on your behalf
- You have been diagnosed with mild-to-moderate Alzheimer's disease for at least 6 months, based on recognised medical guidelines from 2018
- If you do not already have test results confirming Alzheimer's, you must have a brain scan (PET scan) or spinal fluid test during the screening period that shows signs of the protein build-up linked to Alzheimer's
- Your score on a standard memory and thinking test (MMSE) falls between 11 and 26, and your overall dementia rating (CDR-GS) is between 1 and 2
Who may not be able to join:
- You have been diagnosed with a type of memory or thinking problem that is not caused by Alzheimer's disease, such as vascular dementia, Parkinson's-related dementia, Lewy body dementia, frontotemporal dementia, Huntington's disease-related dementia, or dementia caused by thyroid problems, vitamin deficiencies, or other reasons
- You have a history of epilepsy or seizures
- You have been diagnosed with a psychiatric condition such as schizophrenia, bipolar disorder, or delirium
- Your score on a standard depression rating scale (HAMD-17) is 17 or higher
- Your score on a standard anxiety rating scale (HAMA) is 14 or higher
- You are currently taking antidepressants, anti-anxiety medications, or antipsychotic drugs at the time of screening
- Your score on a scale used to assess signs of vascular-related memory problems (HIS score) is 4 or higher (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Xiaochun Chen, Medical Doctor, Fujian Medical University Affiliated Union Hospital
Phone: 028-81258178
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change from baseline to endpoint in Alzheimer's dementia Assessment Scale-Cognitive subscore (ADAS-Cog12).; Change from baseline to endpoint in Clinical Dementia Rating-Sum of Boxes (CDR-SB).
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.